Normalization of Pre-ASCT, FDG-PET Imaging With Second-Line, Non-Cross Resistant, Chemotherapy Programs Improves Event-Free Survival in Patients With Hodgkin Lymphoma

OncologyStat^®One Source, Many Resources.^® By Elsevier

Normalization of Pre-ASCT, FDG-PET Imaging With Second-Line, Non-Cross Resistant, Chemotherapy Programs Improves Event-Free Survival in Patients With Hodgkin Lymphoma

Blood. 2011 Dec 19;[Epub Ahead of Print], CH Moskowitz, MJ Matasar, AD Zelenetz, J Yahalom, et al

TAKE-HOME MESSAGE

Abstract

We previously reported that remission duration <1 year, extranodal disease, and B symptoms prior to salvage chemotherapy (SLT) can stratify relapsed or refractory Hodgkin lymphoma (HL) patients into favorable and unfavorable cohorts. In addition, pre-ASCT FDG-PET response to SLT predicts outcome. This phase II study uses both pre-SLT prognostic factors and post-SLT FDG-PET response in a risk-adapted approach to improve PFS following high-dose radio-chemotherapy (HDT) and ASCT. The first SLT uses...

Comment Print page RSS feeds

About Our Journal Scans

View a list of journals that the OncologySTAT editorial team scans every week in order to bring you the most practice-relevant original research and review articles.

View list ›

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.

Sign-up now ›

Elsevier